Table 3.
Treatment and follow-up data. ACR = biopsy-proven acute cellular rejection; AMR = biopsy-proven antibody-mediated rejection, CsA = cyclosporine; FK = tacrolimus; LDV = ledipasvir; LOS = length of stay; LT = liver transplantation; IMS = immunosuppresion; MMF = mycophenolate mofetil; RBV = ribavirin; SOF = sofosbuvir; VEL = velpatasvir.
| ID | LOS POST- LT |
HCV genotype |
Treatment x weeks |
Days to treatment |
IMS exposure* |
Comments |
|---|---|---|---|---|---|---|
| 1 | 11 | 3 | sof/dcv/rbv x 24 | 84 | FK | None |
| 2 | 15 | 1A | sof/ldv/rbv x 24 | 38 | FK, MMF | None |
| 3 | 10 | 3 | sof/vel x 12 | 47 | FK, MMF | None |
| 4 | 13 | 3 | sof/vel/rbv x 12 | 75 | FK, MMF | None |
| 5 | 24 | 1A | sof/ldv x 12 | 48 | CsA, MMF | AMR treated with IVIG, rituximab† |
| 6 | 7 | 3 | sof/vel/rbv x 12 | 30 | FK, MMF | None |
| 7 | 18 | 1B | sof/vel x 24 | 62 | FK, CsA, MMF, sirolimus |
ACR treated with prednisone‡, AMR treated with IVIG, rituximab, thymoglobulin‡, ACR treated with prednisone |
| 8 | 8 | 1A | sof/vel x 12 | 11 | FK, MMF | None |
| 9 | 16 | 1A | sof/ldv x 12 | 17 | CsA, MMF | None |
| 10 | 26 | 2B | sof/vel x 12 | 15 | CsA, MMF | Mild ACR, no change in IMS ‡ |
*
Exposure during HCV treatment
‡
Occurred prior to initiation of HCV therapy
†
Occurred after completion of HCV therapy